Artelo Biosciences annual shareholders’ equity
2014
2015
2016
2017
2018
2019
2020
2021
2021
2022
2023
2024
2025
Artelo Biosciences Shareholders’ Equity Growth & History (ARTL)
Artelo Biosciences's shareholders’ equity was −$1.3M for fiscal 2025.
View full Artelo Biosciences company overviewArtelo Biosciences annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.3M | −$4.1M | — |
| 2024 | 2024-12-31 | $2.9M | −$8.9M | −75.69% |
| 2023 | 2023-12-31 | $11.8M | −$7.7M | −39.43% |
| 2022 | 2022-12-31 | $19.4M | −$7.8M | −28.58% |
| 2021 · Dec 31 | 2021-12-31 | $27.2M | — | — |
| 2021 · Aug 31 | 2021-08-31 | $12.0M | $8.2M | +210.76% |
| 2020 | 2020-08-31 | $3.9M | −$1.6M | −29.03% |
| 2019 | 2019-08-31 | $5.5M | $5.6M | — |
| 2018 | 2018-08-31 | −$134,974 | −$679,811 | — |
| 2017 | 2017-08-31 | $544,837 | $558,637 | — |
| 2016 | 2016-08-31 | −$13,800 | −$29,690 | — |
| 2015 | 2015-08-31 | $15,890 | $1,159 | +7.87% |
| 2014 | 2014-08-31 | $14,731 | — | — |
Artelo Biosciences quarterly shareholders’ equity
Q4.14
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.0M | $6.4M | — |
| Q1 2026 | 2026-03-31 | $6.7M | $6.0M | +923.31% |
| Q4 2025 | 2025-12-31 | −$1.3M | −$4.1M | — |
| Q3 2025 | 2025-09-30 | −$633,000 | −$7.0M | — |
| Q2 2025 | 2025-06-30 | −$1.4M | −$8.7M | — |
| Q1 2025 | 2025-03-31 | $652,000 | −$8.9M | −93.16% |
| Q4 2024 | 2024-12-31 | $2.9M | −$8.9M | −75.69% |
| Q3 2024 | 2024-09-30 | $6.4M | −$8.2M | −56.37% |
| Q2 2024 | 2024-06-30 | $7.3M | −$9.0M | −55.13% |
| Q1 2024 | 2024-03-31 | $9.5M | −$8.1M | −45.93% |
| Q4 2023 | 2023-12-31 | $11.8M | −$7.7M | −39.43% |
| Q3 2023 | 2023-09-30 | $14.6M | −$7.3M | −33.44% |
| Q2 2023 | 2023-06-30 | $16.3M | −$7.6M | −31.76% |
| Q1 2023 | 2023-03-31 | $17.6M | −$8.1M | −31.58% |
| Q4 2022 | 2022-12-31 | $19.4M | −$7.8M | −28.58% |
| Q3 2022 | 2022-09-30 | $21.9M | — | — |
| Q2 2022 | 2022-06-30 | $23.8M | — | — |
| Q1 2022 · Mar 31 | 2022-03-31 | $25.8M | — | — |
| Q4 2021 · Dec 31 | 2021-12-31 | $27.2M | — | — |
| Q1 2022 · Nov 30 | 2021-11-30 | $28.3M | $19.2M | +212.41% |
| Q4 2021 · Aug 31 | 2021-08-31 | $12.0M | $8.2M | +210.76% |
| Q3 2021 | 2021-05-31 | $11.9M | $8.7M | +269.47% |
| Q2 2021 | 2021-02-28 | $12.9M | $9.1M | +246.70% |
| Q1 2021 | 2020-11-30 | $9.1M | $4.1M | +82.42% |
| Q4 2020 | 2020-08-31 | $3.9M | −$1.6M | −29.03% |
| Q3 2020 | 2020-05-31 | $3.2M | $3.1M | +2299.98% |
| Q2 2020 | 2020-02-29 | $3.7M | $4.4M | — |
| Q1 2020 | 2019-11-30 | $5.0M | $5.4M | — |
| Q4 2019 | 2019-08-31 | $5.5M | $5.6M | — |
| Q3 2019 | 2019-05-31 | $134,379 | $225,724 | — |
| Q2 2019 | 2019-02-28 | −$692,174 | −$907,349 | — |
| Q1 2019 | 2018-11-30 | −$475,164 | −$769,170 | — |
| Q4 2018 | 2018-08-31 | −$134,974 | −$679,811 | — |
| Q3 2018 | 2018-05-31 | −$91,345 | $22,599 | — |
| Q2 2018 | 2018-02-28 | $215,175 | $234,647 | — |
| Q1 2018 | 2017-11-30 | $294,006 | $300,466 | — |
| Q4 2017 | 2017-08-31 | $544,837 | $558,637 | — |
| Q3 2017 | 2017-05-31 | −$113,944 | −$104,475 | — |
| Q2 2017 | 2017-02-28 | −$19,472 | −$15,053 | — |
| Q1 2017 | 2016-11-30 | −$6,460 | −$7,131 | — |
| Q4 2016 | 2016-08-31 | −$13,800 | −$29,690 | — |
| Q3 2016 | 2016-05-31 | −$9,469 | −$22,050 | — |
| Q2 2016 | 2016-02-29 | −$4,419 | −$11,000 | — |
| Q1 2016 | 2015-11-30 | $671 | — | — |
| Q4 2015 | 2015-08-31 | $15,890 | $1,159 | +7.87% |
| Q3 2015 | 2015-05-31 | $12,581 | — | — |
| Q2 2015 | 2015-02-28 | $6,581 | — | — |
| Q4 2014 | 2014-08-31 | $14,731 | — | — |
Artelo Biosciences shareholders’ equity trends
Between the periods ended 2014-08-31 and 2025-12-31, Artelo Biosciences's shareholders’ equity decreased from $14,731 to −$1.3M, a change of −$1.3M. The latest reported quarter, Q2 2026, shows $5.0M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Artelo Biosciences source filings ↗